Latest Developments in Health Care Market Negotiations

Jefferies analysts have published their latest Market Talks covering the Health Care sector, which was exclusively published on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. According to the note from Jefferies analysts, Bayer is facing challenges on multiple fronts that are hastening the need to explore strategic options. The halt of a late-stage clinical trial of experimental cardiovascular drug asundexian pushes financial risk to the edge, while share-price falls increase sensitivity to rising provisions and potential trial losses in a legal battle over its Roundup weedkiller. This suggests that the German pharmaceutical-and-agricultural group might need to sell assets and scrap dividends to buy time. However, this may not be enough to enable large-scale investments needed in its pharma business, Jefferies says. As a result, Jefferies has cut its recommendation on the stock from buy to hold. Despite this, shares trade 0.3% higher following Monday’s heavy losses. (adria.calatayud@dowjones.com) Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8